ArticleScientific reports2020
A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet's syndrome.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Sub-Tenon's triamcinolone bridging to adalimumab therapy in refractory noninfectious uveitic macular edema.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Blood-Ocular Barrier Dysfunction in Uveitis: A Bidirectional Model Linking Pathogenesis, Clinical Monitoring, and Therapeutic Opportunities.Medical sciences (Basel, Switzerland) · 2026Review
- Natural Products Targeting Immune Mechanisms in Ocular Inflammation: Uveitis and Dry Eye.Current issues in molecular biology · 2026Review
- Real-world treatment patterns for patients with non-infectious uveitis in Japan: a descriptive study using a large-scale claims database (J-CAT study).Journal of ophthalmic inflammation and infection · 2025Article
- Ophthalmic Use of Targeted Biologics in the Management of Intraocular Diseases: Current and Emerging Therapies.Antibodies (Basel, Switzerland) · 2024Review
- Indications, response, and side effects of biologic treatment in Behçet's disease: an 8-year study with follow-up.Reumatologia · 2024Article
- Mycophenolate mofetil may be an alternative for maintenance therapy of Behçet syndrome uveitis: a single-center retrospective analysis.Rheumatology international · 2023Article
- Behçet's Disease Uveitis.Journal of clinical medicine · 2023Review
- Long-term outcomes of infliximab in patients with Behçet's disease-associated uveitis.International ophthalmology · 2023Article
- Ten-year follow-up of infliximab treatment for uveitis in Behçet disease patients: A multicenter retrospective study.Frontiers in medicine · 2023Article
- Ocular Manifestations of Behçet's Disease: An Update on Diagnostic Challenges and Disease Management.Journal of clinical medicine · 2021Review
- Old and New Challenges in Uveitis Associated with Behçet's Disease.Journal of clinical medicine · 2021Review
- Behçet syndrome with eye involvement.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infliximab (IFX) was the first biologic introduced for refractory uveitis treatment in Behçet's syndrome (BS). However, there have been few reports on the safety and efficacy of IFX monotherapy over follow-up periods of more than 10 years. This retrospective study evaluated the 10-year safety and efficacy of IFX monotherapy compared to IFX combination therapies with colchicine or corticosteroid for refractory uveitis in BS patients. Monotherapy was performed in 30 eyes of 16 patients while combination therapies were performed in 20 eyes of 11 patients. Continuation of IFX occurred in 70.3% of enrolled patients for 10 years without any significant difference noted in the retention rate between the monotherapy and combination therapies (p = 0.86). Reduction of ocular inflammatory attacks and improvement of best corrected visual acuity occurred in the monotherapy group after 10 years, which was equivalent to that for the combination therapies. Although adverse events (AEs) or therapy discontinuation occurred during the initial 5 years in both therapies, no AEs were observed for either therapy after 6 years. Our results suggested that IFX monotherapy proved to be effective and not inferior to combination therapies over a 10-year follow-up. Although loss of response and AEs may be noticed during the initial 5-year period, a safe and effective continuation can be expected thereafter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.